Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
45.43 USD | +0.60% | +5.72% | -24.50% |
May. 15 | Legend Expects to Log Profit in 2026 | MT |
May. 14 | HC Wainwright Adjusts Price Target on Legend Biotech to $86 From $87, Keeps Buy Rating | MT |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
- According to Refinitiv, the company's ESG score for its industry is poor.
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The opinion of analysts covering the stock has improved over the past four months.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The company appears highly valued given the size of its balance sheet.
- Revenue estimates are regularly revised downwards for the current and coming years.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-24.50% | 8.23B | D | ||
+9.58% | 115B | B+ | ||
+12.41% | 106B | B+ | ||
-2.59% | 21.96B | B | ||
-12.38% | 21.87B | B+ | ||
-5.29% | 19.21B | A- | ||
-3.35% | 18.08B | B | ||
-38.57% | 17.71B | A- | ||
+7.51% | 14.32B | C+ | ||
+35.67% | 12.42B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- LEGN Stock
- Ratings Legend Biotech Corporation